Evidence map›Paper›PMID 28738967›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2017

[Recent Advances in Association of Estrogen and Non-small Cell Lung Cancer].

Xiaosheng Ding, Chuanhao Tang, Zhijie Wang, Jun Liang

Open access · greenAbstract readReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xiaosheng DingDepartment of Oncology, Peking University International Hospital, Beijing 102206, China.
Chuanhao TangDepartment of Oncology, Peking University International Hospital, Beijing 102206, China.
Zhijie WangDepartment of Oncology, Peking University International Hospital, Beijing 102206, China.
Jun LiangDepartment of Oncology, Peking University International Hospital, Beijing 102206, China.
Peking University · CNPeking University International Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer, of which approximately 85% are non-small cell lung cancer (NSCLC), is one of the most prevalent cancers and the most leading cause of cancer mortality. Despite recent improvements in its treatment, the prognosis remains dismal. Previous studies have clearly proved that estrogen and estrogen receptors (ER) are involve in the pathogenesis and development of lung cancer. More and more evidences showed antiestrogen therapy may reverse the drug-resistance of platinum based chemotherapy in NSCLC patients and can enhance curative effect of epidermal growth factor receptor tyrosine kinase inhibitor. We will review recent progress in the function of estrogen in NSCLC and the treatment based on the ER signaling pathways for NSCLC in this article.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungEstrogensHumansLung NeoplasmsReceptors, EstrogenSignal TransductionEstrogensReceptors, Estrogen

Identifiers

PMID28738967
PMCPMC5972945
OpenAlexW2912085708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.